Skip to main content
. 2025 Jul 31;10(8):105540. doi: 10.1016/j.esmoop.2025.105540

Figure 2.

Figure 2

Genomic landscape highlighting MDM2 amplification in the overall population. (A) MDM2 amplification and TP53 mutation status in the overall population. (B) MDM2 gene copy number according to the primary tumor location among patients with MDM2-amp/TP53-WT. (C) Genomic landscape of alterations detected with tissue-based targeted next-generation sequencing (NGS) in the overall population. (D-G) Gene- and pathway-level alterations according to the presence of MDM2-amp/TP53-WT. (D) Top 10 oncogenic alterations in patients with MDM2-amp/TP53-WT. (E) Actionable alterations. (F) Oncogenic signaling pathways. (G) DNA damage repair (DDR) pathways. Statistically significant findings (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001) were obtained with Pearson’s chi-square test or Fisher’s exact test as appropriate. amp, amplification; BER, base excision repair; del, deletion; FA, Fanconi anemia; HR, homologous recombination; MMR, mismatch repair; mut, mutation; NER, nucleotide excision repair; NHEJ, nonhomologous end joining; nonamp, non-amplification; TMB, tumor mutational burden; WT, wild-type.